Jaguar Health Inc (JAGX) Stock Price, Quote & News

Company Profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infe...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 371 8300

Website: jaguar.health

Address:

200 Pine Street, Suite 400, San Francisco, United States

Ozunoy May. 13 at 9:29 AM

$JAGX buy orders around 1.15 ?

1 · Reply

MarketManStockWizzard May. 12 at 9:38 PM

$JAGX Yes, Nasdaq Listing Rule 5635(d) is designed to give shareholders a vote, allowing them to block (vote against) a company issuing 20% or more of its common stock or voting power at below-market prices in private placements. If shareholders reject the proposal, the company cannot proceed with the transaction, effectively preventing it from selling that volume into the market. However, it has been APPROVED. Meaning the company can fully dilute over 20% via last Pre14a proxy. Please have fun, but trade knowing risk reward is paramount here.

0 · Reply

MarketManStockWizzard May. 12 at 9:32 PM

$JAGX have your finger ready to hit the trade button! $40,000,000.00 worth is ony about 11m shares unless the price declines from selling pressure.

0 · Reply

MarketManStockWizzard May. 12 at 9:29 PM

$JAGX

0 · Reply

The_Gambl3r May. 12 at 7:59 PM

$JAGX 👀

0 · Reply

MarketManStockWizzard May. 12 at 7:50 PM

$JAGX https://www.sec.gov/ix?doc=/Archives/edgar/data/0001585608/000119312526164339/d70657dpre14a.htm Under the terms and subject to the conditions of the ELOC Agreement, the Company will agree to sell, and C/M Capital will agree to purchase, up to $40 million (the “Offering Amount”) of the Company’s Common Stock (the “Purchase Shares”), subject to a sale limit of 19.99% of the outstanding shares of the Company’s Common Stock in accordance with Rule 5635(d). The Company would issue the Purchase Shares in reliance upon an exemption from registration contained in Section 4(a)(2) of the Securities Act and Regulation D.

1 · Reply

Omago78 May. 12 at 6:18 PM

$JAGX So... how many new bagholders from this mini pump and dump?

0 · Reply

ScottyDoesntKnowMeSon May. 12 at 4:50 PM

$JAGX because the last reverse splits did great for the company. 2 years ago it was “so hedge funds will buy at $5”. Keep selling urself this turd of a company. This will be on the pink sheets soon.

0 · Reply

andycoolbeans May. 12 at 4:13 PM

$JAGX I’m glad magic man came back after blocking me for embarrassing him. Let’s see some more substance and less Hail Marys please

0 · Reply

MarketManStockWizzard May. 12 at 4:05 PM

$JAGX probably best i dont say anything of substance as it annoys the bulls. As we can see, bagholders were created last 2 days as it drops on 24k volume from recent highs. Nobody caught the high and sold. That definately blows. Anyhoot, just keep eyes peeled for s1. And effect registration.

0 · Reply

Jaguar Health granted extension to comply with Nasdaq bid price rule

May 8, 2026, 9:00 AM EDT - 4 days ago

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

2026-05-07T04:48:16.000Z - 6 days ago

Jaguar Health’s Napo held preliminary discussion with FDA over crofelemer

May 6, 2026, 9:00 AM EDT - 6 days ago

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

2026-05-04T13:09:38.000Z - 8 days ago

Jaguar Health announces planned launch of Neonorm Dog

May 4, 2026, 8:30 AM EDT - 8 days ago

Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

2026-04-29T14:15:11.000Z - 13 days ago

Jaguar Health announces results from trial of crofelemer

Apr 29, 2026, 8:30 AM EDT - 13 days ago

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

2026-04-27T13:41:07.000Z - 15 days ago

Jaguar Health granted extension to demonstrate compliance with Nasdaq bid rule

2026-04-27T13:37:48.000Z - 15 days ago

Jaguar Health announces 1-for-35 reverse stock split

Apr 27, 2026, 9:00 AM EDT - 15 days ago

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

2026-04-24T12:40:01.000Z - 18 days ago

Jaguar Health reports acceptance of abstracts on crofelemer for ESPGHAN meeting

Apr 24, 2026, 8:30 AM EDT - 18 days ago

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Apr 20, 2026, 4:15 PM EDT - 22 days ago

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

2026-04-13T12:43:56.000Z - 4 weeks ago

Jaguar Health plans to U.S. AI platform to enhance crofelemer program objectives

Apr 13, 2026, 8:30 AM EDT - 4 weeks ago

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

Apr 10, 2026, 8:30 AM EDT - 4 weeks ago

Jaguar Health Earnings Call Transcript: Q4 2025

Apr 9, 2026, 8:15 PM EDT - 4 weeks ago

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

2026-04-08T12:50:32.000Z - 4 weeks ago

Jaguar Health completes effectiveness study of crofelemer tablets

Apr 8, 2026, 8:30 AM EDT - 4 weeks ago

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

2026-04-07T14:24:11.000Z - 5 weeks ago

Jaguar Health reports FY25 EPS ($24.27) vs. ($130.69) last year

Apr 7, 2026, 8:30 AM EDT - 5 weeks ago

Jaguar Health Reports 2025 Financials

Apr 2, 2026, 9:00 AM EDT - 5 weeks ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

2026-03-18T13:12:13.000Z - 7 weeks ago

Jaguar Health announces FDA support for Napo’s protocol amendment

Mar 18, 2026, 9:00 AM EDT - 7 weeks ago

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

2026-03-16T13:15:11.000Z - 2 months ago

Magdalena initiates preclinical study of coca for appetite suppression

Mar 16, 2026, 9:00 AM EDT - 2 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Mar 12, 2026, 2:00 PM EDT - 2 months ago

Jaguar Health Transcript: Life Sciences Virtual Investor Forum

Mar 11, 2026, 9:00 AM EDT - 2 months ago

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

2026-03-09T13:22:00.000Z - 2 months ago

Jaguar Health restructures, reduces royalty, debt obligations

Mar 9, 2026, 9:00 AM EDT - 2 months ago

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

2026-03-03T14:10:35.000Z - 2 months ago

Jaguar Health secures $3M payment from Future Pak

Mar 3, 2026, 9:00 AM EST - 2 months ago

Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

2026-03-02T14:14:18.000Z - 2 months ago

Jaguar Health reminds shareholders of record date for special dividend

Mar 2, 2026, 9:00 AM EST - 2 months ago

Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend

2026-02-18T14:10:43.000Z - 2 months ago

Jaguar Health announces special one-time stock dividend

Feb 18, 2026, 9:00 AM EST - 2 months ago

Jaguar Health Announces a Special One-time Stock Dividend

2026-01-22T14:10:42.000Z - 3 months ago

Jaguar Health highlights strategic focus on rare disease development program

Jan 22, 2026, 9:00 AM EST - 3 months ago

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jan 15, 2026, 3:30 PM EST - 4 months ago

Jaguar Health Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 14, 2026, 9:00 AM EST - 4 months ago

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

Jan 12, 2026, 9:00 AM EST - 4 months ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Jan 6, 2026, 9:00 AM EST - 4 months ago

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Jan 2, 2026, 9:00 AM EST - 4 months ago

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Dec 15, 2025, 9:00 AM EST - 5 months ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Dec 10, 2025, 3:25 PM EST - 5 months ago

Jaguar Health Transcript: Emerging Growth Conference 88

Dec 10, 2025, 9:00 AM EST - 5 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Dec 8, 2025, 4:15 PM EST - 5 months ago

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

Dec 2, 2025, 9:00 AM EST - 5 months ago

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Nov 24, 2025, 9:00 AM EST - 6 months ago

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

Nov 20, 2025, 9:00 AM EST - 6 months ago

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

Nov 17, 2025, 8:30 AM EST - 6 months ago

Jaguar Health Earnings Call Transcript: Q3 2025

Nov 17, 2025, 8:00 AM EST - 6 months ago

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

Nov 14, 2025, 9:00 AM EST - 6 months ago

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

Nov 13, 2025, 9:00 AM EST - 6 months ago

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

Nov 6, 2025, 9:00 AM EST - 6 months ago

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

Oct 24, 2025, 4:15 PM EDT - 7 months ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 6, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

Sep 30, 2025, 3:30 PM EDT - 8 months ago

Jaguar Health Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 9:00 AM EDT - 8 months ago

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

Sep 25, 2025, 2:55 PM EDT - 8 months ago

Jaguar Health Transcript: Emerging Growth Conference 2025

Sep 25, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Sep 24, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

Sep 23, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

Sep 5, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Jaguar Health Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Aug 20, 2025, 2:55 PM EDT - 9 months ago

Jaguar Health Transcript: Emerging Growth Conference 85

Aug 19, 2025, 4:15 PM EDT - 9 months ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

Aug 19, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Jaguar Health Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 9 months ago

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

Aug 12, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Jul 17, 2025, 2:55 PM EDT - 10 months ago

Jaguar Health Transcript: Emerging Growth Conference 84

Jul 10, 2025, 8:30 AM EDT - 10 months ago

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jul 8, 2025, 9:00 AM EDT - 11 months ago

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Jun 30, 2025, 9:00 AM EDT - 11 months ago

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jun 26, 2025, 9:00 AM EDT - 11 months ago

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Ozunoy May. 13 at 9:29 AM

$JAGX buy orders around 1.15 ?

1 · Reply

MarketManStockWizzard May. 12 at 9:38 PM

0 · Reply

MarketManStockWizzard May. 12 at 9:32 PM

$JAGX have your finger ready to hit the trade button! $40,000,000.00 worth is ony about 11m shares unless the price declines from selling pressure.

0 · Reply

MarketManStockWizzard May. 12 at 9:29 PM

$JAGX

0 · Reply

The_Gambl3r May. 12 at 7:59 PM

$JAGX 👀

0 · Reply

MarketManStockWizzard May. 12 at 7:50 PM

1 · Reply

Omago78 May. 12 at 6:18 PM

$JAGX So... how many new bagholders from this mini pump and dump?

0 · Reply

ScottyDoesntKnowMeSon May. 12 at 4:50 PM

0 · Reply

andycoolbeans May. 12 at 4:13 PM

$JAGX I’m glad magic man came back after blocking me for embarrassing him. Let’s see some more substance and less Hail Marys please

0 · Reply

MarketManStockWizzard May. 12 at 4:05 PM

0 · Reply

andycoolbeans May. 12 at 3:27 PM

$JAGX I can tell you one thing. Once people start posting random Solicitations to join potential class action lawsuits they are cooked. They literally have nothing else. That’s not even the kitchen sink. That’s I’m too poor to own a kitchen sink.

0 · Reply

andycoolbeans May. 12 at 3:03 PM

$JAGX the trolls must be crying here. Looks like they are easily clearing this bar. Only three more days

0 · Reply

MarketManStockWizzard May. 12 at 12:35 PM

$JAGX were rich now!! Jaguar Health Inc. (JAGX): Securities Investigation - The White Law Group https://share.google/Ltme7eoFqz8sSUXX2

0 · Reply

debbiekatz May. 12 at 11:10 AM

0 · Reply

ScottyDoesntKnowMeSon May. 12 at 2:04 AM

$JAGX

0 · Reply

austinhaleybop May. 11 at 7:48 PM

$BINI $JAGX $GPUS Good lord!

0 · Reply

debbiekatz May. 11 at 5:23 PM

$JAGX this stock just needs volume. if you bought at 3 then i would shoot for 5-6

1 · Reply

FeliciaMath May. 11 at 5:04 PM

still holding $HTCO, $JAGX, $MX, $UGRO

1 · Reply

Omago78 May. 11 at 4:53 PM

$JAGX lol... just started posting here again about a month ago and have zero shares in this scam, But I do know more about the company than the bagholders here. Tell me Ciggy, what are the positives about Jagx that has you here pumping it? It is the fact that they have never made a profit, in fact they have lost roughly $500M since their IPO. Maybe it is their horrendous product line that has little to no market. Could it be their terrible CEO that has already bankrupted one company with this product line. Just think if you were lucky enough to invest a mere 5,796,393,746.64 at teh IPO you would be worth a whopping $3.36 today lol.

1 · Reply

ciggycapital May. 11 at 4:26 PM

$JAGX this guy has posted every single day for 3 years on this board lmaooo can only imagine how much he’s lost. Biggest bag holder of all time?? 🤣🤣🤣🤣 But he will play it off as being a bear to cope. It’s truly embarrassing. He’s BROKE lmaooo 🚬

1 · Reply

Omago78 May. 11 at 4:12 PM

$JAGX Tell me you have no idea about investing without telling me you have no idea about investing lol...

0 · Reply

jeni1988 May. 11 at 3:42 PM

$JAGX 1000$ or better bankrupt

0 · Reply

Market Cap	1.23M
Revenue (ttm)	11.51M
Net Income (ttm)	-53.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-464.21%
Debt to Equity Ratio	-0.81

Volume	37,900
Avg Vol	46,416
Day's Range	N/A - N/A
Shares Out	372,000.00
Stochastic %K	13%
Beta	0.01
Analysts	Strong Buy
Price Target	$16.00